arrow
I

Ioannis E. Κoutroubakis

university hospital of heraklion
H指数:54
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Comprehensive Assessment of the Multifaceted Impact of Inflammatory Bowel Disease on Quality of Life: Insights From the IBD‐PODCAST Study

炎症性肠病多方面对生活质量影响的全面评估:来自IBD‐PODCAST研究的研究发现

2026-11-170
OAAI
Effect of JAK inhibitors on extraintestinal manifestations and concurrent immune-mediated inflammatory diseases in patients with inflammatory bowel disease

JAK抑制剂对炎症性肠病患者肠道外表现和并发免疫介导性炎症性疾病的影响

2026-09-050
PRE
Pancreatic Hyperenzymemia in Inflammatory Bowel Disease: Clinical Characterization and Outcomes from the European PANDORA Registry

炎症性肠病中的胰腺高酶血症:欧洲PANDORA登记研究中的临床特征和结局

2026-07-010
OA
Predictors of Response to Induction Therapy with Ustekinumab in Patients with Ulcerative Colitis: Results from a National Study in Greece

希腊国家研究中溃疡性结肠炎患者对乌司奴单抗诱导治疗的应答预测因子:结果

2026-04-190
OA
Rate and predictors of successful antitumor necrosis factor deescalation after dose intensification in inflammatory bowel disease patients: a real-world Greek-Turkish collaborative study

炎症性肠病患者经剂量强化后肿瘤坏死因子拮抗剂降级治疗的成功率及预测因素:一项希腊-土耳其真实世界合作研究

2026-01-010
PRE
Value of tofacitinib extended induction therapy in patients with moderate-to-severe ulcerative colitis: A real-world 52-week follow-up study

托法替布延长诱导治疗在中重度溃疡性结肠炎患者中的价值:一项真实世界52周随访研究

2025-11-140
PRE
Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class

溃疡性结肠炎中JAK抑制剂的序贯治疗:同类别转换治疗的有效性与安全性

2025-11-030
PRE
Disease Monitoring in Inflammatory Bowel Disease Daily Clinical Practice and Impact on Treatment Decision Making: Real World Evidence From the Inflammatory Bowel Disease-PODCAST Study

炎症性肠病日常临床实践中的疾病监测及其对治疗决策的影响:炎症性肠病-PODCAST研究的真实世界证据

2025-10-130
OAAI
Rate and predictors of successful anti-TNF de-escalation in dose escalated IBD patients. A real-world Greek - Turkish collaborative study
2025-01-220
PRE
Post-Discharge Outcomes of Elderly Patients Hospitalized for Inflammatory Bowel Disease Flare Complicated by Clostridioides difficile Infection
2024-10-210
PRE
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium
2024-07-010
OAAI
Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: A multicenter international study
2024-02-283
OAAI